Predictive value of asprosin combined with LAP for metabolic dysfunction associated steatotic liver disease in the...

To combine two indicators, asprosin and lipid accumulation product (LAP), to assess their predictive value for metabolic dysfunction-associated steatotic liver disease (MASLD) and to provide a more convenient and accurate option for mass screening of the MASLD population. Data were collected from 1249 adult subjects who underwent physical examination, LAP was calculated and serum asprosin was measured. Statistical analyses were performed and ROC curves were constructed to assess the predictive value of asprosin, LAP and their combination for MASLD. Asprosin and LAP levels were significantly higher in the MASLD group than in the non-MASLD group (P < 0.001), and asprosin and LAP were independent risk factors for the development of MASLD (P < 0.05).The combination of asprosin and LAP had the highest predictive efficacy for MASLD, and the AUCs were 0.841, 0.821 and 0.871 in the total, male and female populations, respectively. Asprosin and LAP are both good predictors of MASLD, and their combined performance is better than either indicator alone, and better in women than in men.The combination of asprosin and LAP may be an ideal marker for MASLD screening and individualised monitoring and management.